Compare Merck & Co., Inc. (MRK) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Marsh & McLennan Companies, Inc. — how do they compare? Merck & Co., Inc. trades at $148.18 (market cap $366.28B), while Marsh & McLennan Companies, Inc. trades at $176.89 (market cap $86.15B). The key difference: Merck & Co., Inc. is far larger — about 4.3× Marsh & McLennan Companies, Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.29%). Which is the better fit depends on your goals.
| MRK | MRSH | |
|---|---|---|
Market Cap | $366.28B | $86.15B |
Sector | Health | Financials |
52-Week High | $156.43 | $207.02 |
52-Week Low | $77.60 | $157.32 |
Enterprise Value | $413.04B | $106.83B |
Dividend Yield | 2.29% | 2.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
Marsh & McLennan (MRSH) trades at $180.52, down 2.81% on the day, with a bullish technical signal despite recent weakness. The stock shows strong fundamentals, including consistent earnings beats, a 14.24% net income margin, and robust cash flow. Recent news highlights growth in healthcare consulting and cyber risk services, supporting revenue expansion.
Outlook remains positive with a consensus price target of $208.63, offering 15% upside. Risks include economic sensitivity and debt levels, but analyst sentiment leans bullish with 30% buy ratings. The stock presents a growth opportunity in professional services, backed by solid financials and strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
